Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis

TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

(2012) Charles F Burant et al.   LANCET

The Effect of Oral Antidiabetic Agents on A1C Levels: A systematic review and meta-analysis

(2010) D. Sherifali et al.   DIABETES CARE

Relationship of baseline HbA1cand efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

(2010) R. A. DeFronzo et al.   DIABETIC MEDICINE

Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?

(2010) I. W. Campbell   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Impact of Type of Preadmission Sulfonylureas on Mortality and Cardiovascular Outcomes in Diabetic Patients with Acute Myocardial Infarction

(2010) Marianne Zeller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

(2009) J. Jendle et al.   DIABETES OBESITY & METABOLISM

Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time

(2009) B. Gallwitz et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy

(2008) D. M. Nathan et al.   DIABETOLOGIA